Dr. Lal Pathlabs Ltd. News and Updates

Name: Latest research reports of Dr. Lal Pathlabs Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Dr. Lal Pathlabs Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on Dr. Lal Pathlabs Ltd. from all sources in a single place.

Load latest

Dr. Lal Pathlabs Ltd.

23 Oct 2024

2766.40

-1.45%

to see Rapid results content

Dr. Lal Pathlabs Ltd.

10 Oct 2024

2766.40

-1.45%

More than 85% of cases of vision loss in country preventable: Experts

Business Standard

India has the maximum number of visually challenged people in the world but 85 per cent of the cases of vision loss are preventable or treatable and there was a need to spread awareness about it, experts say. On the occasion of the World Sight Day, the experts noted that India is home to an estimated 34 million people living with blindness or moderate or severe visual impairment (MSVI). Dr Ikeda Lal, senior cornea, cataract and refractory surgery specialist, at Delhi Eye Centre and Sir Ganga Ram Hospital Delhi said, "It is important to spread awareness around preventable blindness because more than 85 per cent of the blindness is preventable if only people know how to address it". The common reasons for blindness in India are cataract, glaucoma, macular degeneration, uncorrected refractive error, diabetic retinopathy and corneal blindness. Unfortunately, people often do not know that all these conditions can be treated and blindness can be reversed, Dr Lal said. Dr Rajesh Sinha, .

Emkay increased Buy price target of Dr. Lal Pathlabs Ltd. to 3100.0 on 26 Apr, 2025.

Dr. Lal Pathlabs Ltd.

23 Sep 2024

2766.40

-1.45%

Price hikes improve margins for diagnostic labs amid online competition

Business Standard

Diagnostic companies like Metropolis Healthcare and Dr Lal PathLabs have implemented price hikes to cope with inflationary pressures

Dr. Lal Pathlabs Ltd. is trading above its 100 day SMA of 2728.7

Dr. Lal Pathlabs Ltd.

23 Sep 2024

2766.40

-1.45%

Dr. Lal Pathlabs - Status Quo On Volumes Implies No Change In Stance: Yes Securities

NDTV Profit

Swasthfit to continue to drive mix change; gradual uptick in specialized portfolio, says the brokerage.

Emkay increased Buy price target of Dr. Lal Pathlabs Ltd. to 3100.0 on 26 Apr, 2025.

Dr. Lal Pathlabs Ltd.

22 Aug 2024

2766.40

-1.45%

DR. LAL PATHLABS LIMITED

Hold: Dr. Lal Pathlabs Ltd.

Recommendation Target

Geojit BNP Paribas

Dr. Lal Pathlabs Ltd. has an average target of 2923.50 from 4 brokers.

Dr. Lal Pathlabs Ltd.

08 Aug 2024

2766.40

-1.45%

Broker's call: Dr Lal Path Labs (Add)

Business Line

Centrum Broking

Emkay increased Buy price target of Dr. Lal Pathlabs Ltd. to 3100.0 on 26 Apr, 2025.

Dr. Lal Pathlabs Ltd.

08 Aug 2024

2766.40

-1.45%

Dr. Lal Pathlabs Results Earnings Call for Q1FY25

Conference Call with Dr. Lal Pathlabs Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.

Dr. Lal Pathlabs Ltd.

08 Aug 2024

2766.40

-1.45%

Dr. Lal Pathlabs Q1 Results Review - Lack Of Volume Traction Keeps Us Away: Yes Securities

NDTV Profit

Margin continues to hold at higher level despite Suburban operating profit margin at 14% and penetration in to tier-III and four towns, says the brokerage.

Dr. Lal Pathlabs Ltd. is trading above its 100 day SMA of 2728.7

Dr Lal PathLabs Q1 results: Net profit up by 29.1%, revenue rises by 11.3%

Business Standard | 07 Aug 2024 2 more

Dr. Lal Pathlabs Ltd.

08 Aug 2024

2766.40

-1.45%

Steady quarter; valuation a bit pricey

Hold: Dr. Lal Pathlabs Ltd.

Target

ICICI Securities Limited

Dr Lal PathLabs’ (Dr Lal) Q1FY25 result was in line with our expectations. Growth was driven by better uptick in Swasthfit (up 26.4% YoY) overall sample volume rose 9.3% YoY.